US pharma giant Merck & Co (NYSE: MRK) on Sunday revealed it has entered into a definitive agreement to acquire clinical-stage biotech Prometheus Biosciences (Nasdaq: RXDX).
Merck, which is looking to add new products to its pipeline as its mega-billion dollar cancer therapy Keytruda (pembrolizumab) is expected to lose patent protectionin2028, is offering to pay $200.00 per share in cash, a 75% premium to Prometheus' Friday closing price of $114.01, or an equity value of around $10.8 billion. Prometheus had a market cap of $5.4 billion as of Friday’s market close, up about 4% year-to-date.
Prometheus’ shares rocketed 70% to $194.01 in pre-market trading today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze